Amgen Expects Palifermin BLA To Clear FDA Shortly
Oral mucositis agent is receiving a "fast track" review, and Amgen is understood to be awaiting word from FDA in the next few days.
Oral mucositis agent is receiving a "fast track" review, and Amgen is understood to be awaiting word from FDA in the next few days.